Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (II): thrombocytopenia and skin manifestations

Cervera, Ricard; Tektonidou, Maria G.; Espinosa, Gerard; Cabral, Antonio R.; González, Emilio B.; Erkan, Doruk; Vadya, S.; Adrogué, Horacio E.; Solomon, Michal; Zandman-Goddard, G; Shoenfeld, Yehuda

doi:10.1177/0961203310395052

Cited by 87 publications

(81 citation statements)

References 70 publications

(96 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with APS may have a broader spectrum of clinical and laboratory manifestations other than stated in those criteria [5], and among various hematologic pathologies described, thrombocytopenia has the leading frequency of occurrence reported in 20-50 % of patients with APS [6]. It is interesting that in some cohorts, the incidence of this non-criteria finding has been reported to be higher than that of criteria findings, and therefore has deserved sufficient attention to be proposed as a part of preliminary classification criteria [7].…”

Section: Introductionmentioning

confidence: 98%

The Significance and Management of Thrombocytopenia in Antiphospholipid Syndrome

2015

View full text Add to dashboard Cite

The association between antiphospholipid antibodies (aPL) and clinical problems goes beyond what is stated in the antiphospholipid syndrome (APS) classification criteria, namely thrombosis and pregnancy morbidity, and thrombocytopenia is the most common non-criteria hematologic manifestation of aPL with a frequency ranging from 20 to 50 %. Thrombocytopenia is rarely severe, and hemorrhage is far less common than thrombosis. However, when anticoagulation is considered, it may constitute a clinical problem with increased bleeding risk. Furthermore, thrombocytopenia represents a risk factor for thrombosis in aPL-positive patients. Therefore, it is important to understand the pathogenesis and the clinical associations of thrombocytopenia to build the right medical approach in aPL-positive patients. In this paper, we review the literature on aPL/APS-associated thrombocytopenia and briefly discuss the other conditions that can result in thrombocytopenia as they have commonalities with APS and their recognition is important to establish the most appropriate treatment strategy.

show abstract

Section: Introductionmentioning

confidence: 98%

The Significance and Management of Thrombocytopenia in Antiphospholipid Syndrome

2015

View full text Add to dashboard Cite

show abstract

“…Occurrence of thrombosis has been reported in 0% to 71% (mean 21%) of ITP patients with aPL [71]. These results suggest that aPL itself may not be sufficient to trigger TEEs.…”

Section: Comorbidities Of Itp As a Possible Risk Factor For Thromboemmentioning

confidence: 96%

“…Antiphospholipid antibodies (aPL) and thromboembolism in ITP patients: A study that summarized data from 9 published series reported that 25-75% (mean 43%) of ITP patients were positive for aPL [71]. aPL includes anticardiolipin antibodies (aCL), anti-ß2-glycoprotein 1 antibodies, and lupus anticoagulant (LA).…”

Section: Comorbidities Of Itp As a Possible Risk Factor For Thromboemmentioning

confidence: 99%

Risk of Thromboembolism in Patients with Immune Thrombocytopenia

Takagi

Suzuki²,

Watanabe³

2015

J Hematol Thrombo Dis

View full text Add to dashboard Cite

Immune thrombocytopenia (ITP) comprises a heterogeneous group of disorders characterized by autoimmunemediated platelet destruction and impairment of platelet production. Thromboembolic events have been reported in up to 8% of patients with ITP, suggesting that thromboembolism requires special precaution in this patient group. Thromboembolism can be caused by a disease (i.e. pro-thrombotic disease state) after the introduction of ITP therapies such as corticosteroids, splenectomy, and thrombopoietin receptor agonists, or can occur in association with other diseases. In the care of patients with ITP, it is important to understand the risk of thromboembolism. In this article, we focus on the risk of ITP-related thromboembolism and potential prevention and management options.

show abstract

“…The most common manifestation is livedo reticularis, which presents as persistent purplish, reddish or bluish lesions, maybe showing a mottled aspect, is irreversible with reheating, and generally affects the trunk, arms, and legs. Besides livedo, cutaneous ulcerations, purpuras, ecchymoses, subungual hemorrhages may also be present (6,15,16) .…”

Section: Discussionmentioning

confidence: 99%

Síndrome antifosfolípide e trombocitopenia na infância

Turini¹,

Chechia²,

Fernandes³

et al. 2012

Rev. paul. pediatr.

View full text Add to dashboard Cite

Objective: To report the case of a child diagnosed with antiphospholipid syndrome associated with severe thrombocytopenia, and to review the literature on the subject.Case description: Child aged nine years and eight months old with severe thrombocytopenia associated with a positive anticardiolipin antibody. Data were collected by clinical history, physical examination, and laboratorial exams. Diagnosis was confirmed according to criteria established for the antiophospholipid syndrome, associated with the presence of the most common manifestations of the syndrome in children: livedo reticularis and thrombocytopenia.Comments: The antiphospholipid syndrome is an uncommon pediatric disease, and clinical manifestations such as decreased platelet number should be considered.

show abstract

Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (II): thrombocytopenia and skin manifestations

Cited by 87 publications

References 70 publications

The Significance and Management of Thrombocytopenia in Antiphospholipid Syndrome

The Significance and Management of Thrombocytopenia in Antiphospholipid Syndrome

Risk of Thromboembolism in Patients with Immune Thrombocytopenia

Síndrome antifosfolípide e trombocitopenia na infância

Contact Info

Product

Resources

About